Soussain, C., Choquet, S., Blonski, M., Leclercq, D., Houillier, C., Rezai, K., Bijou, F., Houot, R., Boyle, E., Gressin, R., Nicolas-Virelizier, E., Barrie, M., Moluçon-Chabrot, C., Lelez, M., Clavert, A., Coisy, S., Leruez, S., Touitou, V., Cassoux, N., Daniau, M., Ertault de la Bretonnière, M., El Yamani, A., Ghesquières, H., & Hoang-Xuan, K. (2019). ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: Final analysis of the phase II 'proof-of-concept' iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network. European journal of cancer, 117, 121–130. http://access.bl.uk/ark:/81055/vdc_100087058180.0x00001e